{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:07:20Z","timestamp":1761743240594,"version":"3.44.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.metabol.2009.03.006","type":"journal-article","created":{"date-parts":[[2009,6,5]],"date-time":"2009-06-05T05:21:14Z","timestamp":1244179274000},"page":"1030-1038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage"],"prefix":"10.1016","volume":"58","author":[{"given":"Paul M.","family":"Coen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa M.","family":"Markofski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandt D.","family":"Pence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"Hannemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2009.03.006_bib1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0140-6736(77)92274-7","article-title":"The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study","volume":"1","author":"Miller","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2009.03.006_bib2","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/01.ATV.14.7.1098","article-title":"Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study","volume":"14","author":"Sharrett","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.metabol.2009.03.006_bib3","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Pedersen","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2009.03.006_bib4","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","author":"LIPID","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2009.03.006_bib5","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2009.03.006_bib6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2009.03.006_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2009.03.006_bib8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2009.03.006_bib9","first-page":"254","article-title":"Statin therapy in clinical practice: new developments","volume":"6","author":"Shepherd","year":"1995","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.metabol.2009.03.006_bib10","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2009.03.006_bib11","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/S0002-9149(03)00003-1","article-title":"Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups","volume":"91","author":"Blasetto","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2009.03.006_bib12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2009.03.006_bib13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/01.CIR.94.4.857","volume":"94","author":"Fletcher","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2009.03.006_bib14","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/oxfordjournals.aje.a115704","article-title":"A meta-analysis of physical activity in the prevention of coronary heart disease","volume":"132","author":"Berlin","year":"1990","journal-title":"Am J Epidemiol"},{"issue":"6 Suppl","key":"10.1016\/j.metabol.2009.03.006_bib15","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1097\/00005768-200106001-00017","article-title":"Physical activity and cardiovascular disease: evidence for a dose response","volume":"33","author":"Kohl","year":"2001","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.metabol.2009.03.006_bib16","series-title":"Exercise and sports science reviews","first-page":"477","article-title":"Effects of exercise training on plasma lipids and lipoproteins","author":"Durstine","year":"1994"},{"key":"10.1016\/j.metabol.2009.03.006_bib17","series-title":"Energy-yielding macronutrients and energy metabolism in sports nutrition","first-page":"87","article-title":"Lipids in exercise and sports","author":"Durstine","year":"2000"},{"key":"10.1016\/j.metabol.2009.03.006_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.ejcn.1600784","article-title":"Exercise training and blood lipids in hyperlipidemic and normolipidemic adults: a meta-analysis of randomized, controlled trials","volume":"53","author":"Halbert","year":"1999","journal-title":"Eur J Clin Nutr"},{"issue":"6 Suppl","key":"10.1016\/j.metabol.2009.03.006_bib19","doi-asserted-by":"crossref","first-page":"S502","DOI":"10.1097\/00005768-200106001-00021","article-title":"Response of blood lipids to exercise training alone or combined with dietary intervention","volume":"33","author":"Leon","year":"2001","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.metabol.2009.03.006_bib20","first-page":"393","article-title":"The effects of exercise on blood lipids and lipoproteins: a meta-analysis of studies","volume":"15","author":"Tran","year":"1983","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.metabol.2009.03.006_bib21","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1139\/h04-052","article-title":"Aerobic exercise, lipoproteins, and cardiovascular disease: benefits and possible risks","volume":"29","author":"Herzberg","year":"2004","journal-title":"Can J Appl Physiol"},{"key":"10.1016\/j.metabol.2009.03.006_bib22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0021-9150(03)00018-2","article-title":"Response of oxidative stress biomarkers to a 16-week aerobic physical activity program, and to acute physical activity, in healthy young men and women","volume":"167","author":"Elosua","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2009.03.006_bib23","first-page":"459","article-title":"Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment","volume":"143","author":"Sinzinger","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2009.03.006_bib24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2710.2001.00360.x","article-title":"Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and\/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy","volume":"26","author":"Sinzinger","year":"2001","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.metabol.2009.03.006_bib25","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/clinchem\/36.12.2145","article-title":"Rhabdomyolysis secondary to lovastatin therapy","volume":"36","author":"Manoukian","year":"1990","journal-title":"Clin Chem"},{"key":"10.1016\/j.metabol.2009.03.006_bib26","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2009.03.006_bib27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archinte.162.12.1329","article-title":"Statin therapy in older persons: pertinent issues","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.metabol.2009.03.006_bib28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1055\/s-2007-1021034","article-title":"Exercise-induced muscle damage","volume":"15","author":"Kuipers","year":"1994","journal-title":"Int J Sports Med"},{"key":"10.1016\/j.metabol.2009.03.006_bib29","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/0026-0495(91)90039-Y","article-title":"Effects of exercise and lovastatin on serum creatine kinase activity","volume":"40","author":"Thompson","year":"1991","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2009.03.006_bib30","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","article-title":"Lovastatin increases exercise-induced skeletal muscle injury","volume":"46","author":"Thompson","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2009.03.006_bib31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2009.03.006_bib32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2003.02044.x","article-title":"Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems","volume":"57","author":"Sinzinger","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2009.03.006_bib33","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","author":"NCEP","year":"2001","journal-title":"JAMA"},{"year":"1995","series-title":"ACSM's guidelines for exercise testing and prescription","author":"ACSM","key":"10.1016\/j.metabol.2009.03.006_bib34"},{"key":"10.1016\/j.metabol.2009.03.006_bib35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1249\/00005768-199301000-00010","article-title":"Measurement of physical activity to assess health effects in free-living populations","volume":"25","author":"Paffenbarger","year":"1993","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.metabol.2009.03.006_bib36","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.metabol.2009.03.006_bib37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0002-9149(01)02226-3","article-title":"Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia","volume":"89","author":"Davidson","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2009.03.006_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-9149(02)02994-6","article-title":"Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease","volume":"91","author":"Schneck","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2009.03.006_bib39","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0002-9149(01)01727-1","article-title":"Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia","volume":"88","author":"Olsson","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2009.03.006_bib40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00007256-199927050-00004","article-title":"Effect of fluvastatin in combination with moderate endurance training on parameters of lipid metabolism","volume":"27","author":"Wittke","year":"1999","journal-title":"Sports Med"},{"key":"10.1016\/j.metabol.2009.03.006_bib41","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cccn.2005.04.032","article-title":"Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease","volume":"360","author":"Ndrepepa","year":"2005","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.metabol.2009.03.006_bib42","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/01.CIR.103.15.1955","article-title":"Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes","volume":"103","author":"Ehara","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2009.03.006_bib43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00041433-200310000-00004","article-title":"Oxidized low density lipoprotein and innate immune receptors","volume":"14","author":"Miller","year":"2003","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.metabol.2009.03.006_bib44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1056-8727(01)00210-0","article-title":"Pathophysiological role of oxidized low-density lipoprotein in plaque instability in coronary artery diseases","volume":"16","author":"Ehara","year":"2002","journal-title":"J Diabet Complications"},{"key":"10.1016\/j.metabol.2009.03.006_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5551\/jat.14.1","article-title":"Measurement of plasma oxidized low-density lipoprotein and its clinical implications","volume":"14","author":"Itabe","year":"2007","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.metabol.2009.03.006_bib46","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2125.2005.02568.x","article-title":"Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy","volume":"61","author":"Resch","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2009.03.006_bib47","doi-asserted-by":"crossref","first-page":"551","DOI":"10.5414\/CPP43551","article-title":"The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients","volume":"43","author":"Thallinger","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.metabol.2009.03.006_bib48","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.atherosclerosis.2005.06.006","article-title":"Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia","volume":"185","author":"van Tits","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2009.03.006_bib49","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.bjp.0707231","article-title":"Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice","volume":"151","author":"Verreth","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.metabol.2009.03.006_bib50","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/147323000703500413","article-title":"Efficacy of atorvastatin therapy in ischaemic heart disease\u2014effects on oxidized low-density lipoprotein and adiponectin","volume":"35","author":"Miyagishima","year":"2007","journal-title":"J Int Med Res"},{"key":"10.1016\/j.metabol.2009.03.006_bib51","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1536\/jhj.45.969","article-title":"Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia","volume":"45","author":"Inami","year":"2004","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.metabol.2009.03.006_bib52","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1194\/jlr.P800030-JLR200","article-title":"Circulating oxidized LDL: determinants and association with brachial flow-mediated dilation","volume":"50","author":"van der Zwan","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2009.03.006_bib53","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0002-9149(02)02355-X","article-title":"The liver and lovastatin","volume":"89","author":"Tolman","year":"2002","journal-title":"Am J Cardiol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049509001024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049509001024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T03:36:15Z","timestamp":1758425775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049509001024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0026049509001024"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2009.03.006","relation":{},"ISSN":["0026-0495"],"issn-type":[{"type":"print","value":"0026-0495"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2009.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}